Significant reduction seen in incidence of major adverse cardiovascular events over median follow-up of 5.1 years<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, July 25, 2023 (HealthDay News) — For patients with HIV infection, those receiving pitavastatin have reduced risk of major adverse cardiovascular events over a median follow-up of 5.1 years, according to a study published online July 23 in the New England Journal of Medicine<\/em> to coincide with the IAS Conference on HIV Science, held from July 23 to 26 in Brisbane, Australia.<\/p>\n Steven K. Grinspoon, M.D., from Massachusetts General Hospital in Boston, and colleagues randomly assigned 7,769 participants with HIV infection and a low-to-moderate risk of cardiovascular disease who were receiving antiretroviral therapy to receive daily pitavastatin calcium or placebo.<\/p>\n After a median of 5.1 years, the trial was stopped early for efficacy. The researchers found that the incidence of a major cardiovascular event was 4.81 and 7.32 per 1,000 person-years in the pitavastatin and placebo groups, respectively (hazard ratio, 0.65). Muscle-related symptoms occurred in 2.3 and 1.4 percent of the pitavastatin and placebo groups, respectively, and diabetes mellitus occurred in 5.3 and 4.0 percent, respectively.<\/p>\n “This observed reduction was larger than that predicted by the Cholesterol Treatment Trialists’ Collaboration on the basis of the achieved reduction in low-density lipoprotein cholesterol levels,” the authors write. “This finding suggests effects on cardiovascular risk beyond those associated with the lowering of LDL cholesterol alone.”<\/p>\n Several authors disclosed ties to pharmaceutical companies, including Kowa Pharmaceuticals America, Gilead Sciences, and ViiV Healthcare, which supported the study.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n